**Reviewer’s Comments**

****

**AN AUDIT OF CURRENT MUCOADHESIVE INTRAVAGINAL DRUG DELIVERY METHODOLOGIES**

**Abstract**

The vaginal course of medication conveyance offers many focal points because of its huge permeation range, rich vascularization, avoidance of first pass metabolism and relatively low enzymatic activity. A few examinations have demonstrated that for sedate organization the vaginal pit is a viable course which expected for the most part for neighborhood activity and conveying drugs for foundational impacts with uterine focusing on. It was first Sobrero who endeavored the vaginal mucosa for tranquilize assimilation, from that point forward much research has been done on the organization of medications through this course. As of late, for vaginal dose frame, different plan and application has expanded impressively. It is fundamentally the conveyance of medications inside or through the vaginal mucosa for neighborhood or foundational pharmacological activity. Degree of medication ingestion and its rate after organization may shift contingent upon vaginal physiology, age of the patient, arrange in the menstrual cycle, neurotic conditions and detailing factors. Here in this audit, there's a feature, the advantages and confinements of vaginal medication conveyance, philosophy in assessment of vaginal medication conveyance frameworks, pharmaceutical viewpoints and an outline of late advances made in the bailiwick of vaginal medication conveyance. Advancement of measurements frame in various stages and in the market, are likewise audited.

**---------------------------------------------------------------------------------------------------------------------**

**Keywords:**Intra-vaginal drug delivery, Vaginal delivery, Microbicide delivery, solubility modifier, First pass metabolism.

**INTRODUCTION**

Coeval researchers have shown their interest onmucoadhesive drug delivery systems among them, vaginal drug delivery system offers a thoroughfare for the release of different antifungal, antibacterial and contraceptive drugs. To improve the vaginal therapy, the formulation administered via the vagina should have more residence time in the vaginal cavity. Conventional vaginal dosages forms have pros and cons both, like they avoid the first pass metabolism, easy to formulate, self-administration, and are economical whereas it producesitching, irritation of vagina, messy to apply, and low residence time respectively. Therefore, to overcome nano drug delivery systems are being formulated. Recently, Nano drug delivery systems like vaginal liposomes, vaginal niosomes, nano suspensions, nano emulsions, nanofibres, have evoked more interest to deliver the drugs via the vaginal route. They offer increased residence time, cellular targeting, localization of formulation to specific sites and mucoadhesion. Various mucoadhesive polymers like hydroxylpropyl methylcellulose (HPMC), chitosan, sodium alginate, eudragit, polycarbophil, carrageenan, hydroxypropyl cellulose, ethylene (vinyl acetate) co- polymer among others have been used for developing novel vaginal formulations. For prevention of HIV and other sexually transmitted diseases (STDs)[1] topical delivery of microbicides is also being investigated as an alternative option.

**Merits of bioadhesive systems over the existing conventional preparations:**

* Excellent accessibility
* Avoidance of aqueous or organic solvents,
* Easy of self-administration
* Gel like consistency in the activated state or at the body temperature
* No irritation
* Rapid bioadhesion, prolonged residence time in the vaginal cavity even in absence of physiological secretions.
* Extended dosing interval.
* Improved chemical and physical stability.[2-7]

Mucoadhesive vaginal delivery systems have both synthetic and natural polymers. Most commonly used mucoadhesive polymers that are capable of forming hydrogels are synthetic polycarbophil, chitosan, cellulose derivatives (hydroxyethycellulose, hydroxypropylcellulose and hydroxypropylmethylcellulose), pectin, hyaluronic acid derivatives, polyacrylates, tragacanth, carrageenan and sodium alginate. New mucoadhesive molecules are thyolated polymers. There bioadhesive properties are cinched by polyacrylic acid-based polymers, known as Carbomers. Mercantilelycarbomers are available in different grade, molecular weight, residual component or degree of cross-linked structure. Among these polymers, polycarbophil and polyacrylic acid are cross-linked with divinylglycol and are more preferred also. These water insoluble polymers have an apparent pKa of approx 4 and picks up 61 - 100 times its weight in water.[8-10]

**Disadvantages [**11-13]

* Gender specificity,
* Patient incompliance,
* Only a few drugs are administered by this route,
* Variability in drug absorption related with menstrual cycle, menopause and pregnancy,
* Influence with sexual intercourse. [13]
* Personal hygiene.
* Some drugs are sensitive at vaginal pH

**ANATOMY AND PHYSIOLOGY OF VAGINA** [14]

The human vagina is a fibro muscular tube which is capable of collapsing. It is a passageway that connects the cervix, which is the opening of the uterus, to the outside of the body. It is also known as the birth canal. The length of the vagina is 6-10 cm which widens from the cervix. The wall of human vagina comprises of three layers such as:

* An outer adventia layer.
* Middle muscular layer.
* The tunica adventia.

It has contours called rugae at the walls of vagina in close juxtaposition to each other which form a collapsible tube. The epithelium portion does not contain any glands, but its surface is kept moist due to cervical secretion, whose composition and volume varies with age, stage of menstrual cycle and degree of sexual excitement. Drug absorbed via the vaginal route which avoids first pass metabolism because the blood leaving from human vagina directly enter into peripheral system through different veins. The normal human vagina lumen has an acidity of around pH 4-5. This vaginal pH is due to the active secretion of ovarian hormones and is also invariantly maintained by the sloughing of mature cells in the upper layers of vaginal mucosa. Due to the influence of estrogen, these cells contain a content of glycogen, which is metabolized to lactic acid in the vaginal canal which maintain the vaginal pH on the acidic side, whereas, the acyclic luteal influence on the vaginal mucosa significantly increases the pH value.

**VAGINAL ANATOMY AND PHYSIOLOGY WITH RESPECT TO DRUG DELIVERY**

The vaginal secretion, pH, enzyme activity and microflora makes the vagina remarkably linguistics. These factors affect formulation spreading, retention, absorption and drug release in vagina.

**Vaginal Secretions:** The release is a blend of numerous emissions that is gathered in the vagina from peritoneal, follicular tubal, uterine, Bartholin's and Skene's organs.[15] Here in nearness of dampness, strong dose plans ought to be in a perfect world scattering in the vaginal trench instantly after inclusion to maintain a strategic distance from bother to the clients.

**Catalyst Activity:** The particular enzymatic action diminishes arranged by four diverse amino peptidases in vaginal homogenates i.e.: sheep > guinea pig > rabbit ≥ human ≥ rodent.[16] The human genital tract has bring down enzymatic action which prompts less debasement of protein and peptide sedates in the vagina than the gastrointestinal tract.

**Vaginal pH:** The pH of the healthy female genital tract is acidic (pH 3.5–4.5) and is maintained within that range by conversion of glycogen from exfoliated epithelial cells to lactic acid through bacteria.[17]Changes in the pH are with age, stage in the menstrual cycle, infections, estrogen levels and variations in the levels of cervical mucus. Asuccessful vaginal drug delivery is a critical factor for controlling the vaginal ph.[18]

The change in hormone levels with age, during intercourse and various phases of the menstrual cycle leads to alteration in vaginal secretion, pH, enzyme activity as well as changes in the thickness and permeability of the epithelium all of which complicate the problem of achieving consistent drug delivery[19].

**MECHANISM**

 The mechanism of mucoadhesion is generally based into two steps;

* Contact stage
* Consolidation stage.

The first stage is an intimate contact, formed between the mucoadhesive and mucous membrane. Initially its contact with the mucus layer is deep. While in the consolidation stage, presence of moisture activates the mucoadhesive material. System is plasticized by moisture and allowing the mucoadhesive molecules to break free and attached by weak Vander Waals and hydrogen bonds. The diffusion theory and the dehydration theory are the two theories that explain the consolidation step. Mucoadhesive molecules and the glycoproteins of the mucus mutually interact and interpenetration their chains and the building of secondary bonds. This is performed according to diffusion theory. For this to take place, the mucoadhesive device favored both chemical and mechanical interactions. For example, molecules having hydrogen bonding groups (-OH, -COOH), high molecular weight, an anionic surface charge, flexible chains and surface-active properties, which helps in spreading throughout the mucus layer.[20-29]

Theories Mucoadhesive is a complex process having numerous theories; their mechanisms are explained as below:

* Wetting theory
* Diffusion theory
* Fracture theory
* Electronic theory
* Adsorption theory

**Wetting Theory**: The wetting theory is the oldest theory of adhesion.Applied on low-viscosity bio adhesive or liquid systems which present affinity to spread over the surface.Predominantly applicable to liquid bioadhesive systems. The thermodynamic work of adhesion is a function of surface tension of the surface in contact as well as interfacial tension. The interfacial energy is responsible for the contact between the two surfaces and adhesive strength. By using measuring techniques such as the contact angel, liquids are spread over the surface and leads to the greater affinity. There is no contact angle to provide good spread ability. The spread ability coefficient (SAB) can be calculated by the difference between the surface energies γB and γA and the interfacial energy γAB. Hence this theory tells about the importance of contact angle and reduces the surface and interfacial energies to gain good amount of mucoadhesion.

SAB = γB – γA – γAB

**Dispersion Hypothesis:** Here the polymer chains and bodily fluid blend to an adequate profundity to make a semipermant cement security. Attachment compel increments with the level of infiltration of the polymer chains and dissemination coefficient have property to improve/diminish the entrance rate of dispersion, adaptability. Nature of the mucoadhesive chains, versatility and contact time likewise rely upon dispersion coefficient. Profundity of interpenetration required to create a productive bioadhesive security lies in the range 0.2-0.5. Given condition is utilized to identify the interpenetration profundity of polymer and mucin chain.

**l = (tDb)**

Where t is the contact time and D expressed asthe diffusion coefficient of the mucoadhesion material in the mucus. To achieve the adhesion strength of polymer, the depth of penetration is approximately equivalent to the chain size of polymers. If components have good mutual solubility then proper diffusion should be occurred. Bio adhesive and the mucus have similar chemical structures. If structural similarity is more than mucoadhesive bond is better.

**Fracture Theory:**The most used theory in studies on the mechanical measurement of mucoadhesion is fractional theory. It attempts to relate the difficulty of separation of two surfaces after adhesion which is used to analyze the force required to separate two surfaces after adhesion is established. This force Sm is calculated in tests of resistance by the ratio of maximal detachment force Fm and the total surface area A0 involved in the adhesive interaction.

**Sm = Fm/A0**

Since the fracture theory is used only for the force required to detach the parts and not used to measure interpenetration or diffusion of polymer chains. It is used to calculate solid or semi-solid bio adhesive materials, in which no penetration of the polymer chain into the mucus layer.

**Electronic Theory:**Hypothesis is used to describe that when when electron exchange between the bodily fluid and the mucoadhesive framework, bond ought to be happened, and through contrasts in their electronic structures is emerge. When electron is transfer between the mucus and the mucoadhesive, double layer of electrical charges at the mucus and mucoadhesive interface is formed. The net result of this process is the formation of attractive forces within the double layer.

**Adsorption Theory:** After an initial contact between two surfaces, the material adheres because of surface forces acting between the atoms in the two surfaces.In this theory, adhesion is the result of various surface interactions (primary and secondary bonding) between the polymer that is adhesive on surface and mucus substrate. Chemisorption required forming primary bonds and ionic, covalent and metallic bonding play an important role in adhesion, which is generally undesirable due to their permanency. Vander walls forces, hydrophobic interactions and hydrogen bonding are responsible for formation of secondary bonds. To break these interactions less energy is required, they are the most well-known from of surface interaction in mucoadhesion process due to having semi-permanent bonds. All these theories are involved in the different stages of the mucus/substrate interaction, rather than individual and alternative theories. These theories are considered as supplementary process. Each and every theory is equally describing the mucoadhesion process. Mucin is initially wetting and then diffusion of the polymer into mucin layer and formation of fractions in the layers, the adhesion or electronic transfer or simple adsorption phenomenon should be affected that finally leads to the perfect mucoadhesion. Formation of mucoadhesive bond is depending on the nature of the mucus membrane, mucoadhesive material, the attachment process and the subsequent environment of the bond.

**VAGINAL ROUTES OF DRUG ABSORPTION**

The drug is delivered in the vagina mainly via two routes: intravaginally to the vaginal epithelium or transvaginal through the vaginal mucosa to uterus and systemic circulation. Cicinelli et al. reported that the vagina has specific blood flow characteristics, either by a portal type circulation or by venous and lymphatic channels that allow bypassing the gastrointestinal tract absorption and liver detoxification and permit preferential transport of drug molecules from the vagina to the uterus and systemic circulation.[30] Several physical models have been devised to study the vaginal permeability of drugs.[31]Antifungal agents such as tioconazole, clotrimazole and miconazole are topically administered to treat vaginal yeast infections. On the basis of our knowledge of anatomical and physiological features of the vagina, it is likely that many other drugs will be formulated for vaginal administration in the future. [32-39]

**Table 1. Influence of Age on the variation of pH, Length, and Width of human Vagina**

|  |  |  |  |
| --- | --- | --- | --- |
| **Changes of vagina** | **pH** | **Length of vagina (cm)** | **Width of vagina(cm)** |
| **Before puberty** | 7 | 4.5-6 | 1-1.5 |
| **Reproductive age** | 4-5 | 10 | 2.5 |
| Adult premenopause | 4-5 | 7-8 | 2 |
| Post-menopause | 4-7 | 4.5-6 | 1-1.5 |

**THE VAGINA AS A SITE FOR MICROBICIDE DELIVERY**

Significant advance has been accounted for in the zone of vaginal microbicides. There are currently more than 50 potentially microbicidal products under development globally, of which 16 are in Phases I-III clinical trials. Recently, the vagina has been rediscovered as potential route for microbicide and contraceptive delivery. Acidform is a gel definition that keeps up a low vaginal pH, immobilizes sperm and forestalls duplication and survival of STD causing creatures.[40-41]Cellulose acetate phthalate based sponges and those made from other cellulose derivatives are soft, mechanically resilient and thus ideally suitable as bio-erodible microbicidal vaginal devices.[42]Conceival is a novel non-toxic, nonspermicidal, selfemulsifying lipophilic gel with improved solubility of lipophilic anti-HIV microbicides.[43] Another vaginal product under development is a liposome preparation containing monoclonal antibodies that will completely agglutinate sperm in the ejaculate.

**PHARMACEUTICAL ASPECTS**

Many pharmaceutical organizations right now concentrate on the advancement of novel vaginal medication conveyance frameworks for treatment of vaginal contaminations, sexually transmitted diseases, contraception and other gynecological conditions. These innovative delivery systems may lead to extended product shelf life making the products competitive in the market place. The option approach of definitions based pharmaceutical organizations is grow new measurements frames utilizing novel excipients that offer particular preferences over ordinary medication conveyance frameworks. With a specific end goal to accomplish alluring medication attributes diverse methodologies are utilized.[44]The compatibility between the drug and excipient can easily be evaluated by thermal (Differential Scanning Calorimetry) and isothermal (HPLC) stress testing.[45]

Penetration Enhancers: Penetration enhancers are capable of promoting absorption and penetration of drug through the vaginal mucosa by decreasing the penetration barrier.[9,46] Currently, the most preferred penetration enhancers include non-ionic surface-active agents, bile salts, benzalkonium chloride, hyaluronic acid[47], polyethylene glycol, ethoxydiglycol and interesterified stone oil.[5,20]

Solubility Modifiers: The poor solubility of drugs in simulated vaginal fluid may affect the release pattern of a drug from its device, which influences the onset and therapeutic efficacy of the drug. Water-soluble drugs are good candidates for vaginal drug delivery. The aqueous solubility of a drug can be increased by several mechanisms such as addition of solubilizing agents and cosolvency.[48] The most commonly used solubilizing agents include citric acid, ethylenediaminetetraacetate, sodium meta-phosphate, polyvinylpyrrolidone, sorbitan, tween 80, polyoxyethylene, polyoxyethylene n-alkyl ethers, poloxamers, and cyclodextrin.[49]For example, a novel itraconazole formulation intended for vaginal use is based on hydroxypropyl-β-cyclodextrin, a functional excipient that increases drug solubility.[50]

Mucoadhesive agents: Mucoadhesive agents permit a close contact of formulation with the vaginal mucosal surface by promoting adherence.[51] These include polycarbophil, hyaluronic acid, chitosan, sodium alginate, tragacanth, carbomer, acacia, sodium carboxymethyl cellulose or other cellulose derivatives, Carbopol 974P-NF, Carbopol 971P-NF and other copolymers of acrylic acid.[52] Some of these polymers may possess sitespecificbioadhesive properties. For example, xanthan gum and sodium alginate show sitespecificbioadhesive properties in a simulated vaginal environment.[53]Polycarbophil 934P exhibited pH-dependent bioadhesive properties.[54]

**CONVENTIONAL VAGINAL DOSAGE FORMULATIONS**

**Vaginal tablet**[54-63]**:** Vaginal tablets are prepared in such a way that they will melt, or disintegrate in the vagina and release the medication in the cavity. Vaginal tablet contains all the excipients of a normal conventional tablet. The tablets are prepared by direct compression method and effervescing agents can be incorporated into formulations to enhance the swellabilty and release of the drug. Tablets offer the advantage of ease of manufacture and insertion. Tablets are stable and less messy to handle than creams or ointments. For example, Clotrimazole vaginal tablet have been used to prevent vaginal candidiasis. Ultra-low dose estriol and Lactobacillus acidophilus vaginal tablets (Gynoflor®) were found to be effective in treating vaginal atrophy in postmenopausal breast cancer patients. Bio adhesive vaginal tablets containing cyclodextrin complex of itraconazole were developed to prevent vaginal candidiasis. Vaginal cream Vaginal creams are used to deliver the antifungal, antibacterial and contraceptive drugs topically. Vaginal creams are messy to apply, uncomfortable and sometimes embarrassing when they leak into the underclothing. Also, the exact dose is not provided because of the heterogeneous distribution of the formulation when applied into the vagina as they are easy to use, for-mulate and are easily available. Premarin vaginal cream is indicated for the treatment of patients with refractory endometria. Conjugated equine estrogen vaginal cream can be used to relieve menopausal atrophic Vaginitis. Bacterial vaginosis can be treated by clindamycin cream.Dienoestrol cream may be useful in the symptomatic prevention of vaginal atrophy in postmenopausal women.Postmenopousal vaginal atrophy can be treated with ovestin vaginal cream and estradiol vaginal cream.

**Vaginal foam**: Vaginal foams are contraceptive foams, used to prevent conception. Spermicide is added in vaginal foam to destroy the sperm and reduce the chances of pregnancy. The foam produces a partition between the sperm and the egg. It is very essential to administer the foam correctly and intercourse should be happening within 1h. Advantages of vaginal foams include availability in market and can be used as a lubricant during sexual intercourse. Different disadvantages have been reported like they produce messiness, not effective against other sexually contagious diseases, may produce inflammation, irritation of vagina, and should be used with other contraceptive device to make it effective. Vaginal froth containing a remedially compelling measure of rifaximin was observed to be helpful in the treatment of vaginal diseases, especially bacterial vaginosis.[64]

**Vaginal gel[**65-71]**:** Vaginal gels containing antibacterial drugs have been used to prevent various vaginal infections. They can also be used to reduce vaginal irritation, discharge and other sexual problems. Bacterial vaginosis is an infection of the vagina caused by overgrowth of the bacteria and this infection can be treated by vaginal gel. Vaginal gels have been commonly used to deliver agents that tighten the vaginal area by contracting the vaginal muscles, helping in enhanced sexual pleasure. In vaginal dryness, gels are used as a lubricant. Some disadvantages of vaginal gels are that they are contraindicated during menstruation and pregnancy. They may suffer from leakiness and messiness. Examples: Hyaluronic acid vaginal gel can be applied in case of vaginal dryness. Researchers have found that certain vaginal gel having antiretroviral drugs may decrease the risk of HIV infection among women.Tenofovir vaginal gel has been investigated in the prophylaxis of HIV. Vaginal suppositories There are a large number of vaginal suppositories in the market which are used to release antifungal and antibacterial drugs in the vagina for different vaginal infections. Reported advantages with vaginal suppositories include avoiding the first pass metabolism, ease to formulate, and self- administration. Different disadvantages are also seen like they produce messiness, less bioadhesion, contraindicated during pregnancy and other sexual problems. For example, vaginal suppositories with lactobacillus were formulated and evaluated to decrease the recurrence of urinary tract infections (UTI) following antimicrobial therapy. Progesterone vaginal suppositories were developed for the prevention of premenstrual syndrome. Prostaglandin suppositories were found to be effective for vaginal infection. Amphotericin B vaginal suppositories were developed for the treatment of non-Candida albicans vaginitis in women. Prostaglandin E2 vaginal suppositories were found to be efficacious in the treatment of persistent postpartum uterine atony.

**Novel Vaginal Dosage Formulations**

**Controlled/sustained release vaginal tablets**

Conventional vaginal tablets release the drug immediately and do not offer prolonged or controlled release of the drugs. Many chronic illnesses and recurrent infections may require prolonged therapy. Therefore controlled/sustained release vaginal tablets have been developed. These tablets may employ various rate sustaining polymers such as hydroxypropyl methylcellulose (HPMC), sodium carboxymethyl cellulose, sodium alginate, ethyl cellulose, guar gum, xanthan gum, etc. Also, the mucoadhesion of the tablets can be improved by using mucoadhesive agents such as chitosan, polycarbophil, etc. Tenofovir vaginal tablet was investigated to deliver tenofovir as a potential HIV microbicide.[72]

**Vaginal ring**[73-80]

Vaginal ring is fabricated by dispersing a contraceptive steroid, such as medroxyprogesterone acetate, as micronized solid particles in a viscous mixture of silicone elastomer and catalyst and then extruding the steroid polymer dispersion into a mould to form a vaginal ring. They are designed to be inserted into the vagina and position around the cervix for 21 days to achieve a constant plasma progestin level and cyclic intravaginal contraception. Reported problem associated with the use of vaginal rings are erosion of vaginal wall, ring expulsion, interference with coitus, unpleasant ring odour, difficulty with storage and sanitation, premature discontinuation due to vaginal discomfort and device related events, including foreign body sensation. For example, Asilastic vaginal ring impregnated with medroxyprogesterone acetate was used as contraceptive device. A novel contraceptive vaginal ring releasing etonogestrel and ethinylestradiol was used to control the menstrual cycle and the bleeding.Oestradiol-releasing vaginal ring has been investigated for the treatment of postmenopausal urogenital atrophy. Novel vaginal danazol ring therapy for pelvic endometriosis has been investigated. Vaginal microspheres Vaginal microspheres are designed as innovative vaginal drug delivery system to impart stability to drug molecules, improve bioavailability and to produce controlled as well as targeted drug release. Bioadhesivemicroparticles and mucoadhesive microspheres are used for better prevention of different diseases. Vaginal microspheres have several advantages such as constant and prolonged therapeutic effect, mucoadhesion, reduction in dose frequency and better patient compliance. But disadvantages also have been reported like higher drug loading required, batch to batch non- uniformity, variation in release rates and toxicity. Econazole nitrate polymer– lipid based vaginal mucoadhesive microspheres were prepared by using spray congealing method.Hyaluronan ester vaginal microspheres were designed for the release of salmon calcitonin to treat the vaginal infection.

**Vaginal nanoparticles**

Because of less duration of action and incomplete coverage, the effect of administered drugs via vaginal route reduces. Therefore, to obtain prolonged release, cellular targeting, and for the treatment of several vaginal infectious disorders, vaginal nano particles have been formulated. These nano particles may contain several mucoadhesive polymers such as chitosan, polycarbophil to improve the mucoadhesion so as to achieve better therapeutic efficacy. Example: mucus penetrating nano particles for vaginal drug delivery were used to protect against herpes simplex virus.[81] Vaginal liposomes consisting small interfering RNA were designed to inhibit different vaginal infectious diseases.[82]

**RECENT DEVELOPMENTS IN VAGINAL DRUG DELIVERY SYSTEM**[83-92]

Vaginal films containing Abacavir, a potent nucleoside reverse transcriptase inhibitor, were designed for the inhibition of sexually transferred diseases. The films were formulated by solvent evaporation method. The resulted films produce extended release of the drugs and they can be applied as novel drug delivery system for the treatment of sexually contagious diseases. Chitosan embedded liposomes incorporating clotrimazole were designed and the results showed it as a promising formulation for vaginal topical therapy. EFdA (a proprietary topical microbicide) films were formulated to treat different sexually transmitted diseases. Fast dissolving films were made with PVA, HPMC E5 and propylene glycol and the produced films were applied intravaginally. The results indicated that they can be used for the effective prevention of HIV infection. Olive oil based emulsion hydrogels have been produced for the treatment of sexually contagious disorders. In this case, sorbitan mono palmitate was added as a structuring agent. The resultant films were biocompatible and showed non-Newtonian flow and can be used to prevent sexually transmitted infections.Curcumin liposomes were prepared for the inhibition of vaginal infections. In this case mucoadhesive polymers like chitosan and Carbopol have been used to prepare the liposomes. Then different physiological properties including mucoadhesion strength were checked and it was revealed that the formulated mucoadhesive liposomes were useful as novel delivery system for vaginal infections. Mucoadhesive caplets of 3′-azido-3′-deoxythimidine and polystyrene sulfonate (anti-HIVdrug) were developed and characterized. Different mucoadhesive polymers like ethyl cellulose, polyacrylic acid have been used to prepare the caplet. The results proved that mucoadhesive caplets of the above drug can be used as potential drug delivery systems for treatment of HIV infected patients.

Bio adhesiveminitablets were formulated and evaluated for the vaginal delivery of hexyl amino levulinate hydrochloride. Different nonionic cellulose ethers and MCC were investigated as matrix forming agents. The resultant mini tablets increased the residence time in the vaginal mucosa and therefore sustained release of the drug can be obtained. Novel silicone elastomer vaginal gels of maraviroc were developed and evaluated. The resultant gels were found to release the drug in a sustained manner. In a study, Cross linked Polyethylene glycol (PEG) based hydrogels of the antimicrobial subtilosin were developed and studied. Characterization study proved that these hydrogels offered extended release of subtilosin for the prevention of bacterial vaginosis. Ethylene-vinyl acetate (EVA) copolymer vaginal rings containing progesterone were developed and evaluated. The rings having silicone were prepared by hot melt extrution method to release progesterone via the vagina. Solid lipid nano particles embodying antifungal drugs like ketoconazole, clotrimazole were prepared and evaluated. In this case PEG 40 stearate has been used and it reacted with acryloyl chloride to form a polymerisable moiety which produced a second shell for slow release of drugs. Then in vitro studies of drug permeability revealed that the nano particles can be used for the inhibition of vaginal infections. UAMC01398, a diaryltriazinenon-nucleoside reverse transcriptase inhibitor was formulated as a gel and evaluated for anti-HIVmicrobicide activity. To produce the best formulation, different hydroxyethyl cellulose based gels were investigated to check their toxicity, stability, ability to enable UAMC01398 epithelial permeation. The result indicated that UAMC01398 has the potential to act as anti-HIV microbicide.42 Curcumin hydroxyl propyl cyclodextrin vaginal films have been formulated to treat cervical cancer caused by Human Papilloma Virus (HPV). In this case, solvent evaporation process was used to form the films by using HPMC E15 and carbopol 934P. It was concluded that these films offered longer residence time in vagina and have the potential to treat HPV induced cervical cancer. Double reservoir polyurethane intravaginal rings were prepared to treat sexually transmitted diseases and uncontrolled pregnancy. Dual reservoir vaginal rings were designed in such a way that they will release tenofovir (HIV- 1 reverse transcriptase inhibitor) and levonorgestrel (contraceptive) for a prolonged period. Oxybutynin vaginal rings for alleviation of overactive bladder symptoms in women have been developed. From the in vivo test it was revealed that these rings were well tolerated and have the potential to act as a novel drug delivery system for the prevention of overactive bladder symptoms.

Lyophilized liposomal gels containing antiviral drug, acyclovir, for the intravaginal delivery were formulated and evaluated. Liposomes were prepared by rotary evaporation method with carbopol and HPMC and subsequently lyophilized. From the evaluation, it was revealed that the carbopol gels showed higher viscosity, spreadability and mucoadhesiveness than the HPMC gels, therefore carbopol liposomal gels were proposed as a promising delivery system of acyclovir via the vaginal route.46 Fluconazole nanofibres have been developed for the management of vaginal candidiasis. Polymeric nanofibres consisting of the drug were formulated by electro spinning method. The resultant nanofibres were found to be effective offering sustained release of drug to treat vaginal infections.Electrospun solid dispersions of maraviroc were formulated and evaluated for constant intravaginal pre- exposure prophylaxis of HIV. The resultant solid dispersions have showed rapid release of maraviroc for the prevention of vaginal infections.

**The list of marketed vaginal products is presented in Table 2.**

|  |  |  |
| --- | --- | --- |
| **Brand Name** | **Active Ingredients** | **App;ication** |
| Replens® | Polycarbophil | Post menupousal atrophy49 |
| Vagifem® | Estradiol hemihydrates | Vaginal atrophy |
| Zendol | Danazol | Endometriosis |
| Nonoxynol-9 | Nonoxynol-9 | Contraceptive |
| Nuvaring® | Etonogestrel/ethinyl estradiol | Contraceptive |
| Nestorone® | Ethinyl estradiol | Contraceptive |
| Gyne-lotrimin® | Clotrimazole | Vaginal yeast infections |
| Monistat® | Miconazole nitrate | Vaginal yeast infections |
| Crinone® | Progesterone | Infertility due to inadequate luteal phase |
| Trivagizole® | Clotrimazole | Vaginal yeast infections |
| Prochieve® | Progesterone | Progesterone deficiency |
| Meprate® | Medroxy progesterone acetate | Endometriosis |

**METHODOLOGY IN EVALUATION OF VAGINAL DRUG DELIVERY SYSTEM**[93]

A vaginal detailing must be assessed by performing both in vitro and in vivo examines. Contingent upon the measurement frame, extra tests for vaginal medication items may incorporate appearance, thickness, pH, molecule estimate examination, disintegration rate, content consistency and microbial points of confinement.

**In vitro studies**

 In vitro studies include the determination of drug release and bio-adhesive characteristics in addition to various physical and chemical properties of formulations . The discharge attributes of a medication from a vaginal detailing can be resolved in recreated vaginal liquid (pH 4.2) and in different disintegration media (pH go 2–12) by various sorts of dispersion cells with specific adjustments and a vaginal disintegration analyzer .The bio-glue quality of the vaginal definition can be measured by different strategies (like Wilhelmy plate surface strategy).

**In vivo studies**

 In different animal models, IN VIVO studies are held for distribution, spreading, retention and to assess efficacyof formulations in the vagina. Assessing the distribution, spreading and retention of vaginal formulations in sheep and humans Gamma scintigraphy and colposcopy are desirable techniques. However, the significance of these findings is debatable. However Magnetic resonance imaging (MRI) and an intravaginal optic probe are the two techniques which are being developed to measure the degree of coverage in the vaginal vault. Various animal models such as sheep, rats, rabbits, rhesus monkeys, macaque monkeys, dogs and mice have been used in different studies in the development of vaginal formulations. While white rabbits are used for primary irritation and subchronic toxicity testing. Recently developed tissue model vaginal-ectocervical (VEC) will serve as a useful, highly reproducible, non-animal tools to assess the irritation due to vaginal care product.

**CONCLUSION**

 Mucoadhesive vaginal drug delivery formulations offer potential improvements in residence time, bioavailability and penetration of drug through mucus membrane of vaginal cavity. It reduces the side effects that are caused by another route of drug administration like avoid first pass metabolism. Mucoadhesive or bioadhesive agents enhance the activity of formulation.

**REFERENCES:**

1. Thakur RS, Khan AB. Microbicides for prevention of AIDS. Current Drug Therapy. 2013; 8(1): 59-67.
2. Robinson JR, Bologna WJ. Vaginal and reproductive system treatments using a bioadhesive polymer. J Cont Rel. 1994; 28(1): 87–94.
3. Acarturkfusun. Mucoadhesive vaginal drug delivery systems. Recent patent on drug and formulation 2009; 3:193-205.
4. Valenta C. The use of mucoadhesive polymers in vaginal delivery. Adv Drug Deliv Rev 2005; 57: 1692-1712.
5. Knuth K, Amiji M, Robinson JR. Hydrogel delivery systems for vaginal and oral applications. Formulation and biological considerations. Adv Drug Deliv Rev 1993; 11: 137-167.
6. Robinson JR, Bologna WJ. Vaginal and reproductive system treatments using a bioadhesive polymer. J Control Release 1994; 28: 87-94.
7. Brannon-Peppas L. Novel vaginal drug release applications. Adv DrugDeliv Rev 1993; 11: 169-177.
8. dasNeves J, Bahia MF. Gels as vaginal drug delivery systems.Int J Pharm 2006; 318: 1-14.
9. Acartürk F, Robinson JR. Vaginal permeability and enzymatic activity studies in normal and ovariectomized rabbits. Pharm Res 1996; 13: 779-783.
10. M. Boddupalli.Bindu, N.K.mohammedZulkar,A.Nath.Ravinder.Mucoadhesive drug delivery system: An over view ,v.1(4);2010
11. Chickering DE, III, Mathiowitz E. Fundamentals of bioadhesion. In: Lehr CM, editor. Bioadhesive drug delivery systemsFundamentals, Novel Approaches and Development. New York: Marcel Dekker; 1999. pp. 1–85.
12. Ahuja A, Khar RK, Ali J. Mucoadhesive drug delivery systems. Drug DevInd Pharm. 1997; 23:489–515.
13. Chang J.Y., Oh V.K., Kong H.S., Kim E.J., Jang D.D., Nan K.T. & Kim C.K., Prolonged Antifungal effect of clotrimazolecontaining mucoadhesive thermosensitive gels on vaginitis, J. control. Release, 2002, 82: 39-50.
14. Platzner W, Poisel S, Hafez ESE. Functional anatomy of the human vagina in: Hafez SE, Evans TN (Eds.), Human reproductive medicine: the human vagina, North Holland Publishing, New York; 1978; 39–54.
15. K.S. Moghissi, Vaginal Fluid Constituents. In The Biology of the Fluids of the Female Genital Tract, Elsevier, North Holland.1979, pp. 13-23.
16. F. Acartürk, and Z.I. Parlatan, J Pharm. Pharmacol., 53 (2001) 1499-1504.
17. E.R. Boskey, R.A. Cone and K.J. Whaley, Hum. Reprod., 16 (2001) 18091813.
18. P.E. Castle, D.A. Karp and L. Zeitlin, J. Reprod. Immunol., 56 (2002) 61-76.
19. A.C. Guyton and J.E Hall, Female Physiology Before Pregnancy, and The Female Hormones, In Textbook of Medical Physiology, W.B. Saunders, Philadelphia, USA. 1998, pp. 1017-1032
20. M.A. D'Augustine, J.H. Liu and D.C. Harrison, U.S. Patent 6,416,779, July 11, 2000.
21. E. Cicinelli, Fertil. Steril., 69 (1998) 471473.
22. P. Van der Bijl, L. Penkler and A. D. Van Eyk, Int J. Pharm., 305 (2005) 105111.
23. M.T. Borin, K.K. Ryan and N.K. Hopkins, J. Clin. Pharmacol., 39 (1999) 805-810.
24. A.P. Gordon-Wright and M.G. Elder, Prostaglandins, 18 (1979) 153-160.
25. G. Constantine, K. Hale and D. Eccleston, J. Clin. Pharm. Ther., 12 (1987) 193-196.
26. M.M. Alper, B.N Barwin and S. Sved, Obstet. Gynecol., 65 (1985) 781-784.
27. H. Vorherr, P. Mehta, J.A. Ulrich and R.H. Messer, JAMA, 244 (1980) 26282629.
28. B.N. Swanson, R.K. Lynn and N. Gerber, J. Pharmacol Exp. Ther., 206 (1978) 507-514.
29. L.G Patel, Br. Med. J., 287 (1984) 12471248.
30. E.T. Houang and A.G. Lawrence, Antimicrob. Agents Chemother., 27(1985) 964-965.
31. E. Amaral, A. Perdigao and M. H. Souza, Contraception, 70 (2004) 492-507.
32. E. Amaral, A. Perdigao and M. H. Souza, Contraception, 73 (2006): 542-547.
33. A.R. Neurath and N. Strick, U.S. Patent 6,572,875, June 3, 2003.
34. O.J. D’Cruz, P. Samuel and F.M. Uckun, AAPS PharmSciTech., 06 (2005) E56E64.
35. S. Garg, K. Tambwekar, K. Vermani, A. Garg and L.J.D. Zaneveld, Pharm. Technol. 25 (2001) 14-24.
36. R. Kandarapu, V. Grover and S. Garg, STP Pharm Sci., 11 (2001) 449-457.
37. J.R Robinson, X. Absorption Enhancers. In Encyclopedia of Pharmaceutical Technology; J. Swarbrick and J.C. Boylan, Eds, Marcel Dekker, Inc. New York, vol 18, 1999, pp. 1-27.
38. G. Sandri, S. Rossi, F. Ferrari, M.C. Bonferoni, N. Zerouk and C. Caramella, J. Pharm. Pharmacol. 56 (2004) 10831090.
39. T. Higuchi and K. Connors, Adv. Anal. Chem. Instrum., 4 (1965) 117-212.
40. T. Loftsson and M. Brewster, J. Pharm. Sci., 85 (1996) 1017-1025.
41. M. Francois, E. Snoeckx, P. Putteman, F. Wouters, E. De Proost, U. Delaet, J Peeters and M.E. Brewster, AAPS PharmSci. 5 (2003) 1-5.
42. J. Woodley, Clin. Pharmacokinet., 40 (2001) 77-84.
43. C. Valenta, Adv. Drug Del. Rev., 57 (2005) 1692-1712
44. H. Blanco-Fuente and J. Blanco-Mendez, Int. J. Pharm., 142 (1996) 169-174.
45. K. Vermani, S. Garg and L. Zaneveld, Drug Dev. Ind. Pharm., 28 (2002) 11331146.
46. Roth AC, Milsom I, Forssman L, Wahlen P. Intermittent prophylactic treatment of vaginal tablet. Genitourin Med. Oct 1990; 66(5): 357-60.
47. Dondors G, Neven P, Moegele M, Lintermans A, Bellen G, Prasauskaus V, et al. Ultra low dose estradiol and Lactobacillus acidophilus vaginal tablets (Gynoflor) for vaginal atrophy in post-menopausal breast cancer patients on aromatic inhibitors: Pharmacokinetic, safety and efficacy phase 1 clinical study. Breast Cancer Res Treat. 2014; 145(2): 371–9.
48. Cevher E, Acma A, Sinani G, Aksu B, Zloh M, Mülazımoğlu L. Bioadhesive tablets Containing cyclodextrin complex of itraconazole for the treatment of vaginal candidiasis. Inter J Biol Mole. August 2014; 69: 124–36.
49. Zolghadr J, Haghbin H, Dadras N, Behdin S. Vagifem is superior to vaginal premarin in induction of endometrial thickness in the frozenthawed cycle patients with refractory endometria: A randomized clinical trial. Iran J Reprod Med. Jun 2014; 12(6): 415-20.
50. Rosemary A, Giselle M, Atice L, Elizabeth A, Edith W, Ingemar S, et al. A comparative study of safety and efficacy of continuous low dose oestradiol released from a vaginal ring compared with conjugated equine oestrogen vaginal cream in the treatment of postmenopausal urogenital atrophy. B J O G. April 1996; 103(4): 351-8.
51. McGregor JA, French JI, Jones W, Milligan K, McKinney PJ, Patterson E, et al. Bacterial vaginosis is associated with prematurity and vaginal fluid mucinase and sialidase: results of a controlled trial of topical clindamycin cream. Amer J ObstAndGyne. April 1994; 170(4): 104860.
52. Bygdeman M, Swahn ML. Replens versus dienoestrol cream in the symptomatic treatment of vaginal atrophy in postmenopausal women. Maturitas April 1996; 23(6): 259-63.
53. Kicovic PM, Cortes-prieto J, Milojevic, Haspels AA, Aljinovic A. The treatment of postmenopausal vaginal atrophy with ovestin vaginal cream or suppositories: clinical, endocrinological and safety aspects. Maturitas December 1980; 2(4): 275–82.
54. Dickerson J, Bressler R, Christian CD, Hermann HW. Efficacy of estradiol vaginal cream in postmenopausal women. ClinPharmaco and Therap. 1979; 26(4): 502-7.
55. Egidio M, Gabriele RL, Subhash D, Massimo G. inventor, Alfa Wassermann S.P.A. Pharmaceutical compositions containing rifaximin for treatment of vaginal infections. US 5314904 A; 1994 May 24.
56. Chen J, Geng L, Song X, Li H, Giordan N, Liao Q. Evaluation of the Efficacy an Safety of hyaluronic acid vaginal gel to ease vaginal cryness: a multicenter, randomized, controlled, open-label, parallelgroup, clinical trial. J sexu Med. June 2013; 10(6): 1575-84.
57. Morrow KM, Underhill K, Berg JV, Vargas S, Rosen RK, Katz DF. User- identified gel characteristics: a qualitative exploration of perceived product efficacy of topical vaginal microbicides. Arch Sex Behav. Oct 2014; 43(7): 1459-67.
58. Hendrix mail CW, Chen BA, Guddera V, Hoesley C, Justman J, Nakabiito C, et al. Randomized Pharmacokinetic Cross-Over Study Comparing tenofovir vaginal gel and Oral tablets in vaginal tissue and other compartments. PLOS. January 30, 2013; 8(1): e55013. DOI: 10.1371/journal.pone.0055013.
59. Reid G, Bruce AW, Taylor M. Influence of three-day antimicrobial therapy and Lactobacillus vaginal suppositories on recurrence of urinary tract infections. ClinThera. 1992; 14(1): 11-6.
60. Maddocks S, Hahn P, Moller F, Reid RL. A double-blind placebocontrolled trial of progesterone vaginal suppositories in the treatment of premenstrual syndrome. Amer J ObstGyne. March 1986; 154(3): 573-81.
61. Shepherd JH, Bennett LM. Prostaglandin Vaginal suppositories: A simple and safe Approach to the Induction of Labor. ObstGyne. November 1981; 58(5): 596-600.
62. Phillips AJ. Treatment of non-albicans Candida vaginitis with amphotericin B vaginal suppositories. Amer J ObstGyne. June 2005; 192(6): 2009-12.
63. Hertz RH, Sokol RJ, Dierker LJ. Treatment of postpartum uterine atony with prostaglandin E2 vaginal suppositories. ObstGyne. 1980; 56(1): 129-30.
64. Mcconville C, Friend DR, Clark MR, Malcolm K. Preformulation and development of a once-daily sustained-release tenofovir vaginal tablet containing a single excipient. J Pharm Sci. June 2013; 6(102): 1859-68.
65. Mishell DR, Talas M, Parlow AF, Moyer DL. Contraception by means of a silastic vaginal ring impregnated with medroxyprogesterone acetate. Amer J ObstAndGyne. May, 1970; 107(1): 100-3.
66. Roumen FJME, Apter D, Mulders TMT, Dieben TOM. Efficacy, tolerability and acceptability of a novel contraceptive vaginal ring releasing etonogestrel and oestradiol. Hum Repro. 2001;16(3); 469-75
67. Smith P, Heimer G, Lindskog M, Ulmsten U. Oestradiol-releasing vaginal ring for treatment of postmenopausal urogenital atrophy. Maturitus March 1993; 16(2): 145–54.
68. Igarashi M, Iizuka M, Abe Y, Ibuki Y. Novel vaginal danazol ring therapy for pelvic endometriosis, in particular deeply infiltrating endometriosis. Hum Reprod. 1998; 13(7): 1952-6.
69. Albertini B, Passerini N, Sabatino MD, Vitali B, Brigidi P, Rodriguez L. Polymer-lipid based mucoadhesive microspheres prepared by spraycongealing for the vaginal delivery of econazole nitrate. Euro J Pharm Sci. 2 March 2009; 36(4-5): 591-601. 2
70. Rochira M, Miglietta MR, Richardson JL, Ferrari L, Beccaro M, Benedetti L. Novel vaginal delivery systems for calcitonin: II. Preparation and characterization of HYAFF® microspheres containing calcitonin. Inter J Pharmaceu. 1996; 144(1): 19-26.
71. Ensign LM, Tang BC, Wang Y, Tse TA, Hoen T, Cone R, et.al. MucusPenetrating Nano particles for Vaginal Drug Delivery Protect Against Herpes Simplex Virus. SciTransl Med. 13th June 2012; 4(138): 138.
72. Woodrow KA, Cu Y, Booth CJ, Saucier-Sawyer JK, Wood MJ, Saltzman WM. Intravaginal gene silencing using biodegradable polymer nano particles densely loaded with small- interfering RNA. Nature Materials 3 May 2009; 8(6): 526–533.
73. Ghosal K, Ranjan A, Bhowmik BB. A novel vaginal drug delivery system: anti-HIV bioadhesive film containing abacavir. Jour Mater Sci. July 2014; 25(7): 1679-89.
74. Joraholmen MW, Vanic J, Tho I, Skalco- Basnet N. Chitosan-coated liposomes for topical vaginal therapy: Assuring localized drug effect. Inter J Pharm. 10 September 2014; 472(1-2): 94-101.
75. Zhang W, Parniak MA, Sarafianos SG, Cost MR, Rohan LC. Development of a vaginal delivery film containing EFdA, a novelantiHIV nucleoside reverse transcriptase inhibitor. Inter J Pharm. 30 January 2014; 461(1-2): 203-13.
76. Singh VK, Ramesh S, Pal K, Anis A, Pradhan DK, Pramanik K. Olive oil based novel thermo-reversible emulsion hydrogels for controlled delivery applications. Jour Mater Sci. March 2014; 25(3): 703-21.
77. Berginc K, Suljakovic S, Skalko-Basnet N, Kristl A. Mucoadhesive liposomes as new formulation for vaginal delivery of curcumin. Euro J Pharm Biopharm. May 2014; 87(1): 40-6.
78. Ndesendo VMK, Choonara YE, Meyer LCR, Kumar P, Tomar LK, Tyagi C, et al. In vivo evaluation of a mucoadhesive polymeric caplet for intravaginal anti-HIV-1 delivery and development of a molecular mechanistic model for thermo chemical characterization. Drug development and industrial pharmacy August 11, 2014; 0(0): doi:10.3 109/03639045.2014.947506.
79. Hiorth M, Nilsen S, Tho I. Bioadhesive Mini-Tablets for Vaginal Drug Delivery. Pharmaceutics 2014; 6(3): 494-511.
80. Forbes CJ, Mccoy CF, Murphy DJ, Woolfson AD, Moore JP, Evans A, et al. Modified Silicone Elastomer Vaginal Gels for Sustained Release of Antiretroviral HIV Microbicides. J Pharm Sci. May 2014; 103(5): 142232.
81. Rajan SS, Cavera VL, Zhang X, Singh Y, Chikindas ML, Sinko PJ. Polyethylene Glycol-Based Hydrogels for Controlled Release of the Antimicrobial Subtilosin for Prophylaxis of Bacterial Vaginosis. Antimicrob Agents Chemother. 2014; 58(5): 2747-53.
82. Helbling IM, Ibarra JCD, Luna JA. The Optimization of an Intravaginal Ring Releasing Progesterone Using a Mathematical Model. Pharm Res. March 2014; 31(3): 795-808. 41. Cassano R, Ferrarelli T, Mauro MV, Cavalcanti P, Picci N, Trombino S. Preparation, characterization and in vitro activities evaluation of solid lipid nano particles based on PEG-40 stearate for antifungal drugs vaginal delivery. Drug Delivery. July 9, 2014; 0(0): doi:10.3109/10717 544.2014.932862.
83. Grammen C, Arien KK, Venkatraj M, Joossens J, Veken PVD, Heeres J, et al. Development and in vitro evaluation of a vaginal microbicide gel formulation for UAMC01398, a novel diaryltriazine NNRTI against HIV-1. Anti res. January 2014; 101: 113-21.
84. Umme H, Shivakumar HG, Heena A, Younus PM. Preparation and Optimization of Curcumin-Hydroxy Propyl CyclodextrinBioadhesive Vaginal Films for Human Papilloma Virus-Induced Cervical Cancer. J BiomTissEngn. October 2014; 4(10): 796-803.
85. Clark JT, Clark MR, Shelke NB, Johnson DJ, Smith EM, Andreasen AK, et al. Engineering a Segmented Dual-Reservoir Polyurethane Intravaginal Ring for Simultaneous Prevention of HIV Transmission and Unwanted Pregnancy. PLOS. March 05, 2014; 9(3): e880509. DOI: 10.1371/journal.pone.0088509.
86. Gittelman M, Weiss H, Seidman L. A Phase 2, Randomized, DoubleBlind, Efficacy and Safety Study of Oxybutynin Vaginal Ring for Alleviation of Overactive Bladder Symptoms in Women. The Journal of urology April 2014; 191(4): 1014–21.
87. Manne N, Yadav HKS, Kumar SH, Khom TC, Kumar NS. Design and evaluation of a lyophilized liposomal gel of an antiviral drug for intravaginal delivery. J App Poly Sci. 29 Aug 2013; 131(2): DOI: 10.1002/app.39804.
88. Sharma R, Garg T, Goyal AK, Rath G. Development, optimization and evaluation of polymeric electrospunnanofiber: A tool for local delivery of fluconazole for management of vaginal candidiasis. Artificial cells, Nanomedicine, and biotechnology. October 15, 2014; 0(0): 1-8. doi:10. 3109/21691401.2014.966194.
89. Chang J.Y.,Oh Y.K,. Kim Y.B and. Kim C.K, Int. J. Pharm., 2002;241: 155-163.
90. Bouckaert S., J. Pharm. Pharmacol., 1995; 47 :970-971.
91. Ceschel G.C., Maffei P. and Rossi S., Drug Dev. Ind. Pharm., 2001; 27: 541-547 40. Pavelie Z. andJalsenjak I., J. Control. Rel., 2005 ;106: 34-43.
92. Pekka L. and Harri J., British Medical Bulletin, 2000; 56: 739-748. 42. Neurath A.R and Strick N., U.S. Patent, 2003; 6: 572,875,
93. Alam A.M., Ahmad J.F., Khan I.Z., Khar K.R. & Ali M., Development and evaluation of acid buffering bioadhesive vaginal tablet for mixed vaginal infections. AAPS Pharm Sci. Tech.,2007, 8(4): E1-E8.